A peer-reviewed study reports that one liver-targeted base-editing infusion suppressed ANGPTL3 protein by more than 90% for three years in nonhuman primates. Animal lipid levels also fell substantially, but human efficacy and long-term safety remain unproven as an early clinical trial begins.